Pharma

Your Article Summary

See Latest Articles

Angiotech pharmaceuticals, inc. announces financial results for the second quarter ended june 2009
Angiotech Pharmaceuticals, 08/10/09

Angiotech Pharmaceuticals, Inc. announced its financial results for the second quarter ended June 2009. "We were pleased to observe continued sales growth in our Proprietary Medical Products business during the quarter, including continued acceleration of our important Quill SRS and HemoStream product lines," said Dr. William Hunter, President and CEO of Angiotech. "Despite the continued challenges we are experiencing in certain parts of our Base Medical Products business, the continued stabilization of our TAXUS–derived royalty revenue, the possibility that Cook's Zilver paclitaxel–eluting peripheral stent may contribute additional royalty revenue and the recent FDA approval of our Option Inferior Vena Cava Filter leave us optimistic about the second half of 2009 and 2010."

Today in Financial Reports...keeping you current

Receive free subspecialty "5-minute updates" via email

Abbott Declares 344th Consecutive Quarterly Dividend
Abbott, 12/15/09

Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering
Dendreon Coproration, 12/15/09

Pre-Budget Report response - GSK comments on patent box
GlaxoSmithKline, 12/11/09

 See all of Financial Reports